methods of reducing immunogenicity against factor viii in subjects undergoing factor VIII therapy

摘要

the present disclosure provides methods of administering chimeric and hybrid factor viii (fviii) polypeptides comprising fviii and fc to subjects at risk of developing inhibitory fviii immune responses, including anti-fviii antibodies and / or cell-mediated immunity. the administration is sufficient to promote coagulation and to induce immune tolerance to fviii. the chimeric polypeptide can comprise full-length fviii or a fviii polypeptide containing deletion, e.g., a full or partial deletion of the b domain. "methods of reducing immunogenicity against factor viii in subjects undergoing factor VIII therapy". the present disclosure provides methods of administering the hybrid factor viii (fviii) chemically and polypeptides which are understood to be fviii and fc to the subject at risk of developing an inhibitory immune response of fviii, including anti-fviii antibodies and / or immunity mediated by cells. the administration is sufficient to promote coagulation and to induce the immunological tolerance of fviii. the chimeric polypeptide may comprise full length fVIII or a fVIII polypeptide containing a deletion, for example a total or partial deletion of the b domain.